Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B Among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2021 Apr 27

PMID 33903902

Citations 6

Authors

Kathleen N Ly

Jian Xing

Philip R Spradling

Affiliations

Soon will be listed here.

Abstract

Background: After decades of decline, US acute hepatitis B incidence flattened since 2011. In persons aged ≥40 years and in jurisdictions affected by the opioid crisis, there is an increase in new cases. Data suggest new infections are occurring among US-born persons.

Methods: We used National Health and Nutrition Examination Survey data during 2001-2018 to examine changes in total antibody to hepatitis B virus core antigen (anti-HBc) prevalence in US-born persons. During 2013-2018, the distribution of characteristics was examined.

Results: During 2001-2006, 2007-2012, and 2013-2018, anti-HBc prevalence was 3.5%, 2.5%, and 2.6% among US-born persons, respectively. This corresponded to 5.7 (range, 4.8-6.6) million US-born persons with resolved or current HBV infection during 2013-2018, including 344 600 persons aged 6-29 years. The largest increase and highest prevalence was among persons who reported injection drug use (IDU), which increased from 35.3% during 2001-2006 to 58.4% during 2013-2018 (P = .07).

Conclusions: Anti-HBc prevalence among US-born persons remained flat during the most recent period, coinciding with a doubling of prevalence among persons reporting IDU. These data are consistent with acute hepatitis B surveillance trends, showing increasing incidence in subpopulations where prevention could be strengthened.Anti-HBc prevalence among US-born persons decreased from 2001-2006 to 2007-2012 and remained flat during 2013-2018, coinciding with a near doubling of prevalence among US-born persons reporting a history of injection drug use.

Citing Articles

Vaccination Campaign against Hepatitis B Virus in Italy: A History of Successful Achievements.

Stroffolini T, Stroffolini G Vaccines (Basel). 2023; 11(10).

PMID: 37896935 PMC: 10610604. DOI: 10.3390/vaccines11101531.

Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study.

Marzo B, Vidal-Jordana A, Castillo J, Robles-Sanchez M, Otero-Romero S, Tintore M J Neurol. 2023; 271(1):134-140.

PMID: 37695530 PMC: 10769953. DOI: 10.1007/s00415-023-11973-y.

A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma.

Stroffolini T, Stroffolini G Cancers (Basel). 2023; 15(8).

PMID: 37190317 PMC: 10136487. DOI: 10.3390/cancers15082388.

Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.

Conners E, Panagiotakopoulos L, Hofmeister M, Spradling P, Hagan L, Harris A MMWR Recomm Rep. 2023; 72(1):1-25.

PMID: 36893044 PMC: 9997714. DOI: 10.15585/mmwr.rr7201a1.

Supporting syringe services programs in the initiation and scale-up of vaccine administration: findings from in-depth interviews.

Carry M, Bixler D, Weng M, Doshani M, Roberts E, Montgomery M Harm Reduct J. 2022; 19(1):100.

PMID: 36050735 PMC: 9435406. DOI: 10.1186/s12954-022-00681-x.

References

Roberts H, Kruszon-Moran D, Ly K, Hughes E, Iqbal K, Jiles R . Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 2015; 63(2):388-97. DOI: 10.1002/hep.28109. View

. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982; 31(24):317-22, 327-8. View

Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward J . Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(1):1-31. PMC: 5837403. DOI: 10.15585/mmwr.rr6701a1. View

Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1-33. View

Hofmeister M, Rosenthal E, Barker L, Rosenberg E, Barranco M, Hall E . Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology. 2018; 69(3):1020-1031. PMC: 6719781. DOI: 10.1002/hep.30297. View

Smith B, Morgan R, Beckett G, Falck-Ytter Y, Holtzman D, Teo C . Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012; 61(RR-4):1-32. View

Comer M, Matthias J, Nicholson G, Asher A, Holmberg S, Wilson C . Notes from the Field: Increase in Acute Hepatitis B Infections - Pasco County, Florida, 2011-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(7):230-231. PMC: 5858044. DOI: 10.15585/mmwr.mm6707a6. View

Harris A, Iqbal K, Schillie S, Britton J, Kainer M, Tressler S . Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013. MMWR Morb Mortal Wkly Rep. 2016; 65(3):47-50. DOI: 10.15585/mmwr.mm6503a2. View

Shing J, Ly K, Xing J, Teshale E, Jiles R . Prevalence of Hepatitis B Virus Infection Among US Adults Aged 20-59 Years With a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016. Clin Infect Dis. 2019; 70(12):2619-2627. PMC: 7286375. DOI: 10.1093/cid/ciz669. View

10.

. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep. 1988; 37(24):377-82, 387-8. View

11.

Wasley A, Kruszon-Moran D, Kuhnert W, Simard E, Finelli L, McQuillan G . The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202(2):192-201. DOI: 10.1086/653622. View

12.

Mast E, Margolis H, Fiore A, Brink E, Goldstein S, Wang S . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54(RR-16):1-31. View

13.

Klevens R, Liu S, Roberts H, Jiles R, Holmberg S . Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health. 2014; 104(3):482-7. PMC: 3953761. DOI: 10.2105/AJPH.2013.301601. View

14.

Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G . Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019; 67(5152):1419-1427. PMC: 6334822. DOI: 10.15585/mmwr.mm675152e1. View

15.

Parker J, Talih M, Malec D, Beresovsky V, Carroll M, Gonzalez J . National Center for Health Statistics Data Presentation Standards for Proportions. Vital Health Stat 2. 2018; (175):1-22. View

16.

Ingram D, Malec D, Makuc D, Kruszon-Moran D, Gindi R, Albert M . National Center for Health Statistics Guidelines for Analysis of Trends. Vital Health Stat 2. 2018; (179):1-71. View

17.

Koziol D, Holland P, Alling D, Melpolder J, Solomon R, Purcell R . Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med. 1986; 104(4):488-95. DOI: 10.7326/0003-4819-104-4-488. View

18.

Edlin B, Eckhardt B, Shu M, Holmberg S, Swan T . Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015; 62(5):1353-63. PMC: 4751870. DOI: 10.1002/hep.27978. View

19.

Stevens C, AACH R, Hollinger F, Mosley J, SZMUNESS W, Kahn R . Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med. 1984; 101(6):733-8. DOI: 10.7326/0003-4819-101-6-733. View